



Supplementary figures & tables

Low molecular weight inhibitors targeting the RNA-binding protein HuR

Benjamin Philipp Joseph ^{1,2,#}, Verena Weber ^{1,2,#}, Lisa Knüpfer³, Alejandro Giorgetti^{1,4}, Mercedes Alfonso-Prieto¹, Sybille Krauß^{3,*}, Paolo Carloni^{1,2,*} and Giulia Rossetti^{1,5,6,*}

¹ Institute for Neuroscience and Medicine and Institute for Advanced Simulations (INM-9/IAS-5), Computational Biomedicine, Forschungszentrum Jülich, 52425 Jülich, Germany

² Faculty of Mathematics, Computer Science and Natural Sciences, RWTH Aachen, 52062 Aachen, Germany

³ Institute of Biology, University of Siegen, 57076 Siegen, Germany

⁴ Department of Biotechnology, University of Verona, 37134 Verona, Italy


⁵ Jülich Supercomputing Center (JSC), Forschungszentrum Jülich, 52425 Jülich, Germany

⁶ Department of Neurology, RWTH Aachen University, 44517 Aachen, Germany

Shared first authorship

* Correspondence: sybille.krauss@uni-siegen.de, p.carloni@fz-juelich.de, g.rossetti@fz-juelich.de

58



59

Figure S1. Molecular structures of the HuR inhibitors tested *in vivo*. **(A)** MS-444 (also under preclinical trials). **(B)** KH-3, **(C)** KH-3 derivative 1, **(D)** KH-3 derivative 2, **(E)** Embelin, **(F)** Okicenone, **(G)** Triptolide, **(H)** Leptomycin B, **(I)** Selinexor, **(J)** Mitoxantrone and **(K)** Suramin.

62




Figure S2. Bar plot representing the number of molecules of the first 20 most populated clusters from the HTVS experiment.







Figure S3. Cluster representatives for the 20 most populated clusters.






71

72











Figure S4. Protein-ligand interaction fingerprints for the 20 most populated clusters. Different interaction types are discriminated using the following color code: blue: hydrogen bonds, orange: hydrophobic interactions, green: π - π -stacking, red: π -cation interaction, purple: salt bridges




82



83





86

87

Figure S5: PLIFs of the other 12 bought compounds (C1) derivative, Z259632494; (C2) derivative, Z57908816; (C5) representative, 7643436; (C6) derivative, STK217448; (C7) member, STL170802; (C8) derivative, 5974204; (C9) member, Y044-6405; (C11) representative, STK018404; (C12) derivative, Z373002224; (C13) derivative, STK806137; (C15) derivative, STK593921; (C16) derivative, STL148963; (C19) representative, STL522523. Different interaction types are discriminated using the following color code: blue: hydrogen bonds, orange: hydrophobic interactions, green: π - π -stacking, red: π -cation interaction, purple: salt bridges

94




Figure S6: (A) Surface representation of HuR RRM1/2 (PDB code 4ED5) with the two docked ligands STK018404 (green carbons) and STL170802 (orange carbons) and the residues Lys92 (left) and Arg97 (right) as purple surface. (B) Docking pose in licorice fashion of compound STK018404 (green carbons) and STL170802 (cyan carbons) with labeled residues within 4 Å of the ligands with the protein backbone as cartoon representation with alpha-helices in magenta, beta-sheets in cyan and coils in gray.




Figure S7: Uncropped western blot gels corresponding to the RNA pull-down assays shown in Figure 4 in the main text. (A) RNA–protein pull-down of HuR with its target RNA motif (AU-UUUUAUUUU) in the absence (positive control) or presence of the respective compounds (final concentration 100 μM). RNA-bound proteins were analyzed on western blots detecting HuR. A negative control that does contain RNA and a positive control with no compound were included. (B) RNA–protein pull-down of HuR as described in (A) with different concentrations of the compound STK018404.

Table S1. List of previously reported small molecule inhibitors of the HuR protein as of January 2023.

#	Compound name	Status	IC ₅₀ [μM]	PubChem ID	Ref.
1	MS-444	<i>In vivo</i>	2.1-40.7	132904	29
2	Dehydromutactin	<i>In vitro</i>	39.0-130.0	54685140	29
3	Okicenone	<i>In vitro</i>	0.53-2.9	132015	29
4	Quercetin	<i>In cell</i>	5.78-31.04	5280343	26
5	6n	<i>In cell</i>	0.015	137652621	23
6	24	<i>In vitro</i>	-	-	38
7	CMLD-1	<i>In vitro</i>	5.98	16060621	27
8	CMLD-4	<i>In vitro</i>	5.22	24868003	27
9	CMLD-5	<i>In vitro</i>	9.13	16746465	27
10	CMLD-6	<i>In vitro</i>	8.88	16746321	27
11	CMLD-3	<i>In vitro</i>	7.11	16746461	27
12	31	<i>In vitro</i>	44.4	265580	28
13	32	<i>In vitro</i>	21.7	137651476	28
14	23	<i>In vitro</i>	41.0	66672	28
15	30	<i>In vitro</i>	41.9	54677920	28
16	MPT0B098	<i>In vitro</i>	0.08-0.51	50898338	62
17	SP600125	<i>In vitro</i>	0.12-16.0	8515	9
18	Trichostatin A	<i>In vitro</i>	-	444732	9
19	5-aza-2-deoxycytidine	<i>In vivo</i>	0.01-0.05	460487	9
20	N-Benzylcantharidinamide	<i>In vitro</i>	50.0-100.0	-	63
21	Triptolide	<i>In vivo</i>	0.01-0.03	107985	33
22	Leptomycin B	<i>In vivo</i>	0.01	6917907	34
23	Selinexor	<i>In vivo</i>	0.12-0.22	71481097	35

24	Latrunculin A	<i>In vitro</i>	0.33-0.76	445420	64
25	Blebbistatin	<i>In cell</i>	0.43-22.8	3476986	64
26	Mitoxantrone	<i>In vivo</i>	0.01-1.13	4212	38
27	Suramin	<i>In vivo</i>	732	5361	37
28	NSC 5836	<i>In vitro</i>	14.7	3034178	28
29	NSC 7572	<i>In vitro</i>	41.0	66672	28
30	NSC 44750	<i>In vitro</i>	26.9	239577	28
31	NSC 50648	<i>In vitro</i>	97.4	242249	28
32	NSC 62685	<i>In vitro</i>	16.7	247668	28
33	NSC 123418	<i>In vitro</i>	69.9	276150	28
34	NSC 143491	<i>In vitro</i>	21.7	9575999	28
35	NSC 227186	<i>In vitro</i>	41.9	54706138	28
36	NSC 651084	<i>In vitro</i>	17.4	6713252	28
37	Myricetin	<i>In vitro</i>	1.0	5281672	26
38	b-40	<i>In cell</i>	0.38	1806245	65
39	Ellagic acid	<i>In vitro</i>	0.6	5281855	26
40	(-)-Epicatechin gallate	<i>In vitro</i>	0.2	107905	26
41	Rhamnetin	<i>In vitro</i>	1.2	5281691	26
42	Cryptotanshinone	<i>In cell</i>	6.0	160254	39
43	(-)-Epigallocatechin gallate	<i>In vitro</i>	0.2	65064	26
44	Dihydrotanshinone (DHTS)	<i>In vivo</i>	0.84-1.2	5316743	39
45	6a	<i>In cell</i>	0.0128	132251303	23
46	b-41	<i>In cell</i>	6.21	58739563	65
47	b-68	<i>In cell</i>	-	1801337	65
48	a-63	<i>In cell</i>	-	6161395	65
49	Azaphilone-9	<i>In vitro</i>	51.9-67.6	57326411	49

50	CMLD-2	<i>In vitro</i>	4.44	16746438	27
51	Tanshinone I	<i>In cell</i>	-	114917	39
52	HuR inhibitor 5	<i>In cell</i>	15-27	3634762	47
53	1	<i>In vitro</i>	-	156010691	21
54	2	<i>In vitro</i>	-	155560371	21
55	3	<i>In vitro</i>	-	155517914	21
56	4	<i>In vitro</i>	-	155540762	21
57	Hyperoside	<i>In vitro</i>	-	5281643	55
58	Rutin	<i>In vitro</i>	-	5280805	55
59	Isovitexin	<i>In vitro</i>	-	162350	55
60	Vitexin-2-O-rhamnoside	<i>In vitro</i>	-	5282151	55
61	Aesculin	<i>In vitro</i>	-	5281417	55
62	Novobiocin	<i>In vitro</i>	-	54675769	55
63	Chlorogenic acid	<i>In vitro</i>	-	1794427	55
64	7-hydroxymatairesinol	<i>In vitro</i>	-	44147426	55
65	Colchicoside	<i>In vitro</i>	-	92763	55
66	Asiaticoside	<i>In vitro</i>	-	11954171	55
67	Embelin	<i>In cell</i>	-	3218	32
68	KH-3	<i>In cell</i>	3.34	45138018	36
69	KH-3 derivative 1 (1c)	<i>In cell</i>	4.74	155343380	36
70	KH-3 derivative 2 (7c)	<i>In cell</i>	1.31	11187381	36

117

118

119